Songli Pharmaceutical-B (01672) has selected the same class of first-in-class oral small molecule GIPR agonist ASC48 and oral small molecule GLP-1R agonist ASC30 for the development of fixed-dose combination formulations for clinical development.

Zhitong Financial News App News, Gaili Pharmaceutical-B (01672) announced that it has selected ASC48, a promising first-in-class oral small molecule GIPR agonist, and a fixed-dose combination formulation of ASC30, an oral small molecule GLP-1R agonist, for clinical development. The fixed-dose combination formulation of ASC30 and ASC48 (ASC30_48 FDC) simultaneously targets GLP-1R and GIPR, aiming to be the first-in-class "one-pill, once-daily" oral therapy for obesity.